Morgan Stanley

Morgan Stanley’s wealth division reported a record $232 billion in net new assets, a 57% quarter-over-quarter increase and 187% year-over-year, with more than half tied to IPO-related flows including SpaceX. Wealth net revenue rose to $9.06 billion, up 10% year-over-year, while net interest income was $2.23 billion. The equities division also outperformed expectations with $5.8 billion in revenue, and the firm expects continued benefit from upcoming IPOs such as Anthropic and OpenAI. » Mere på wealthmanagement.com

Quantexa was honored with the Innovation Award 2026 during Morgan Stanley Tech Week for its entity-resolution technology, which consolidates customer data across business lines. The platform uses dynamic matching with an automated and data-steward–assisted review mode to identify duplicate records and enable a holistic customer view. Quantexa positions this as the foundation for Morgan Stanley’s integrated-firm strategy and further AI-powered client intelligence initiatives. » Mere på finanzen.net

Morgan Stanley has launched a digital asset lab to experiment with stablecoins, tokenized deposits, central bank digital currencies (CBDCs) and DeFi applications. Special focus is on DeFi vaults as automated asset pools that could take on fund functions, though the technology is still too immature for production use. The lab complements steps such as the preliminary conditional approval for Morgan Stanley Digital Trust, the Morgan Stanley Bitcoin Trust (spot ETF) and the launch of crypto trading on E*Trade; nothing changes for clients in the short term, but the tests are intended to form the basis for future products. » Mere på deraktionaer.de

Morgan Stanley accidentally disclosed an internal list of 100+ deals it was working on or monitoring, mainly in Asia. Several clients and buy-side sources said they plan to stick with the bank and that many of the disclosed deals were already widely known. Bankers caution the fallout could vary by client and that competitors might spot missed opportunities, but the incident is unlikely to cause widespread loss of mandates or fundamentally erode client trust. » Mere på cnbc.com

At the Morgan Stanley Global Healthcare Conference, Zenas BioPharma reported a liquidity position of roughly $674 million plus up to $150 million in event financings, which the company believes could fund it through Q2 2029. The focus was on Obexelimab, whose BLA is under FDA review (PDUFA date end of May 2025); management said it could differentiate from UPLIZNA and rituximab due to weekly subcutaneous dosing and an inhibitory mechanism. Zenas also presented its broader immunology pipeline, including orelabrutinib for progressive MS, oral IL‑17 and TYK2 candidates, and plans for Europe and China activities; AI is used mainly for data analysis and commercial insights. » Mere på de.investing.com